...the deal was terminated shortly afterwards. Valeant gained the product in its 2005 acquisition of Xcel Pharmaceuticals Inc....

...payment to Meda from Valeant, which gained the compound through its 2005 acquisition of Xcel Pharmaceuticals Inc. Xcel...
...payment to Meda from Valeant, which gained the compound through its 2005 acquisition of Xcel Pharmaceuticals Inc. Xcel...

...Almac launched its XCEL array biomarker discovery technology to identify biomarkers in multiple disease areas. The...

...through its acquisition of Viatris GmbH & Co. Viatris granted rights to the compound to Xcel Pharmaceuticals Inc....

...through its acquisition of Viatris GmbH & Co. Viatris granted rights to the compound to Xcel Pharmaceuticals Inc....

...potassium channel opener and potentiator of GABA. Valeant gained retigabine through its 2005 acquisition of Xcel Pharmaceuticals Inc....

...will fund development of the other compounds. Valeant gained retigabine through its 2005 acquisition of Xcel Pharmaceuticals Inc....

...GSK funding development of the other compounds. Valeant gained retigabine through its 2005 acquisition of Xcel...

...for placebo. RESTORE2 has an SPA from FDA. Valeant gained retigabine through its acquisition of Xcel Pharmaceuticals Inc....

...in patients with epilepsy. The company, which acquired the compound through its 2005 acquisition of Xcel...